KPMA suggested special tax privileges for R&D to extend.

Published: 2006-09-07 07:00:00

Updated: 2006-09-07 07:00:00

The Ministry of Finance and Economy earlier disclosed the revised draft of the special tax privilege act in advance, which restricted the pharmaceutical industry for the R&D investment and the new drug development by eliminating the special tax privileges given to the pharmaceutical technology tr...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK